https://www.marketscreener.com/quote/stock/BASILEA-PHARMACEUTICA-AG-130199/news/Basilea-Reports-Updated-Interim-Results-for-iCCA-Patients-with-FGFR2-Mutations-and-Amplifications-fr-37623796/?utm_source=telegram&utm_medium=social&utm_campaign=share